Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy

AIDS Patient Care and STDs

Volumn 26, Issue 6, 2012, Pages 307-311

  Esker, Stephen ^a   Albano, Jessica ^b   Uy, Jonathan ^a   Arikan, Dilek ^a   Jimenez Exposito, Maria Jesus ^a   Seekins, Daniel ^a   Tilson, Hugh ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b SYNEOS HEALTH   (United States)

^c IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; RITONAVIR;

ANTIVIRAL THERAPY; BIRTH DEFECT; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; PLACENTAL TRANSFER; PRACTICE GUIDELINE; PREGNANCY; PRENATAL DRUG EXPOSURE; PREVALENCE; RISK ASSESSMENT; TREATMENT INDICATION; VIRUS TRANSMISSION;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTI-HIV AGENTS; DATA COLLECTION; FEMALE; HIV INFECTIONS; HUMANS; OLIGOPEPTIDES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, FIRST; PYRIDINES; REGISTRIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84862160591     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0444     Document Type: Letter

References (12)

1. European AIDS Clinical Society. Guidelines: Clinical management and treatment of HIV infected adults in Europe-version 6.1. European AIDS Clinical Society Web site. www .europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ eacsguidelines-v6-1-english.pdf (Last accessed November 2011).
2. Panel on Treatment of HIV-1 Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. AIDSinfo Web site. http://aidsinfo.nih.gov/contentfiles/PerinatalGL .pdf (Last accessed September 14, 2011.
3. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304: 321-333.
4. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2006;7:487-503. (Pubitemid 44742349)
5. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women. HIV Med 2008;9:452-502.
6. Watts DH. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002;346:1879-1891.
7. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2011. The Antiretroviral Pregnancy Registry Web site. www.APRegistry .com (Last accessed October 5, 2011).
8. Molina JM, Andrade-Villaneuva J, Echevarria J, et al. Oncedaily atazanavir/ritonavir compared with twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53:323-332.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. Department of Health and Human Services. www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Last accessed October 14, 2011).
10. Covington DL, Tilson H, Elder J, et al. Assessing teratogenicity of antiretroviral drugs: Monitoring and analysis plan of the Antiretroviral Pregnancy Registry. Pharmacoepidemiol Drug Saf 2004;13:537-545. (Pubitemid 39214032)
11. Centers for Disease Control and Prevention. Basic facts about birth defects: What is a birth defect? www.cdc.gov/ncbddd/ birthdefects/facts.html (Last accessed November 16, 2011).
12. Covington DL, Doi PA, Tilson H, et al. Antiretroviral Pregnancy Registry conforms with FDA Guidelines for Pregnancy Exposure Registries [abstract]. Pharmacoepidemiol Drug Saf 2003;12(Suppl 1):S22.